# Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

> **NCT06360419** · PHASE3 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 346 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Solriamfetol 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06360419
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-26
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360419, "Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06360419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*